[1] Bagcchi S. WHO's global tuberculosis report 2022. Lancet Microbe, 2023; 4, e20.
[2] Singh B. Bedaquiline in drug-resistant tuberculosis: a mini-review. Curr Mol Pharmacol, 2023; 16, 243−53.
[3] Espinosa-Pereiro J, Sánchez-Montalvá A, Aznar ML, et al. MDR tuberculosis treatment. Medicina (Kaunas), 2022; 58, 188.
[4] Van Crevel R, Critchley JA. The interaction of diabetes and tuberculosis: translating research to policy and practice. Trop Med Infect Dis, 2021; 6, 8.
[5] Tiberi S, Utjesanovic N, Galvin J, et al. Drug resistant TB - latest developments in epidemiology, diagnostics and management. Int J Infect Dis, 2022; 124 Suppl 1, S20-5.
[6] Chen XH, Hashizume H, Tomishige T, et al. Delamanid kills dormant mycobacteria in vitro and in a guinea pig model of tuberculosis. Antimicrob Agents Chemother, 2017; 61, e02402−16.
[7] Li Y, Sun F, Zhang WH. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: promising but challenging. Drug Dev Res, 2019; 80, 98−105.
[8] Ryan NJ, Lo JH. Delamanid: first global approval. Drugs, 2014; 74, 1041−5.
[9] Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012; 366, 2151−60.
[10] Khoshnood S, Taki E, Sadeghifard N, et al. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant mycobacterium tuberculosis. Front Microbiol, 2021; 12, 717045.
[11] Liu YG, Matsumoto M, Ishida H, et al. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis, 2018; 111, 20−30.
[12] Guglielmetti L, Chiesi S, Eimer J, et al. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective. Future Microbiol, 2020; 15, 779−99.
[13] Huerga H, Khan U, Bastard M, et al. Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with Bedaquiline, Delamanid, and other second-line drugs. Clin Infect Dis, 2022; 75, 1307−14.
[14] Liebenberg D, Gordhan BG, Kana BD. Drug resistant tuberculosis: implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol, 2022; 12, 943545.
[15] Olayanju O, Esmail A, Limberis J, et al. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J, 2020; 55, 1901181.
[16] Hewison C, Khan U, Bastard M, et al. Safety of treatment regimens containing Bedaquiline and Delamanid in the endTB cohort. Clin Infect Dis, 2022; 75, 1006−13.
[17] Dooley KE, Rosenkranz SL, Conradie F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis, 2021; 21, 975−83.
[18] Vambe D, Kay AW, Furin J, et al. Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini. Int J Tuberc Lung Dis, 2020; 24, 1095−102.
[19] Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis, 2022; 76, e938−46.
[20] Gupta R, Wells CD, Hittel N, et al. Delamanid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2016; 20, 33−7.
[21] Borah P, Deb PK, Venugopala KN, et al. Tuberculosis: an update on pathophysiology, molecular mechanisms of drug resistance, newer anti-TB drugs, treatment regimens and host- directed therapies. Curr Top Med Chem, 2021; 21, 547−70.
[22] Tanneau L, Svensson EM, Rossenu S, et al. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis. CPT Pharmacometrics Syst Pharmacol, 2021; 10, 1538−49.
[23] Putra ON, Yulistiani Y, Soedarsono S. Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis. Int J Mycobacteriol, 2022; 11, 349−55.
[24] Lönnroth K, Williams BG, Cegielski P, et al. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol, 2010; 39, 149−55.
[25] Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis, 2015; 60, 188−94.
[26] Zhao Y, Fox T, Manning K, et al. Improved treatment outcomes with Bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study. Clin Infect Dis, 2019; 68, 1522−9.
[27] Kawai V, Soto G, Gilman RH, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg, 2006; 75, 1027−33.
[28] Yang QL, Han JJ, Shen JJ, et al. Diagnosis and treatment of tuberculosis in adults with HIV. Medicine, 2022; 101, e30405.
[29] Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: current status and future perspectives. J Glob Antimicrob Resist, 2021; 25, 48−59.